secwatch.observer — SEC 8-K summary
======================================

Issuer:     EXELIXIS, INC. (EXEL)
CIK:        0000939767
Form:       8-K
Filed at:   2025-02-11T23:59:59+00:00
Accession:  0000939767-25-000017
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Exelixis Q4 2024 rev $567M, GAAP EPS $0.48; FY2024 rev $2.17B, EPS $1.76
------------------------------------------------------------------------

- Total revenues $566.8M for Q4 2024, up 18% YoY; FY2024 total rev $2.17B, up 18% YoY.
- GAAP diluted EPS $0.48 (Q4 2024) vs $0.27 (Q4 2023); FY2024 $1.76 vs $0.65.
- Non-GAAP diluted EPS $0.55 (Q4 2024) vs $0.33; FY2024 $2.00 vs $0.90.
- Cabozantinib franchise U.S. net product revenues $515M (Q4), $1.81B (FY2024), up from $429M and $1.63B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/939767/000093976725000017/0000939767-25-000017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/939767/000093976725000017/exel-20250211.htm
  HTML page:      https://secwatch.observer/filing/0000939767-25-000017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer